Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28163566 | 0.81 | MGAM (0.35) | — | |
| SCHEMBL6545278 | 0.81 | TSHR (0.38) | — | |
| SCHEMBL12540531 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL26108395 | 0.79 | — | — | |
| SCHEMBL6545080 | 0.77 | TSHR (0.42) | ALDH1A1 | |
| SCHEMBL4447710 | 0.77 | KDM4E (0.30) | — | |
| SCHEMBL6309457 | 0.76 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL15093996 | 0.76 | — | — | |
| SCHEMBL12227359 | 0.76 | LDHA (0.33) | CYP2C19 | |
| SCHEMBL3295212 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115176-A1 | Complement Modulators and Related Methods | RA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-3947352-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020205501-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| EP-3655388-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | Trucode Gene Repair, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-3601237-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | Trucode Gene Repair, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110740994-A | Peptide Nucleic Acid (PNA) monomers with orthogonally protected ester moieties | 特鲁科德基因修复公司 | 2020-01-31 | — | — | CN | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | NEUBASE THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| WO-2018175927-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | TRUCODE GENE REPAIR, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115176-A1 | Complement Modulators and Related Methods | C5, C9, C1QBP | TRPA1 4444/4885ALDH1A1 4659/4885CYP2C19 2587/4885 |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | TRPA1 1545/4885ALDH1A1 4569/4885CYP2C19 4732/4885 |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | TRPA1 2731/4885ALDH1A1 4394/4885CYP2C19 4495/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | TRPA1 1545/4885ALDH1A1 4569/4885CYP2C19 4732/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | TRPA1 2731/4885ALDH1A1 4394/4885CYP2C19 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.